December 2nd 2021
Researchers calculated that 262,591 people in the United States received an hypertrophic cardiomyopathy diagnosis in 2019, an increase of 60% from 164,403 calculated to have been diagnosed in 2013.
December 1st 2021
A new meta-analysis of research finds that a history of previous cardiac events puts children with hypertrophic cardiomyopathy at risk for cardiac death.
November 20th 2021
The decision on the fate of the novel therapy for hypertrophic cardiomyopathy was delayed because the agency said it needed more time to consider the risk evaluation and mitigation strategy (REMS) for the drug.
November 12th 2021
November 11th 2021
In an interview with Managed Healthcare Executive®, Ty Gluckman, M.D., FACC, FAHA, provides helpful explanations of hypertrophic cardiomyopathy diagnosis and treatment
A Primer on HCM, Part 1
In an interview with Managed Healthcare Executive®, Ty Gluckman, M.D., FACC, FAHA, explains the definition, incidence and pathophysiology of hypertrophic cardiomyopathy.
A Window into the HCM Experience
Interviews with 32 patients shows a wide range of experiences but authors say one takeaway is a need for better coordination between HCM specialist and community cardiologists.
Disease-associated Genetic Variants Common Among Those With Early-onset Afib, Study Finds
1 in 10 patients with early-onset atrial fibrillation have gene variants associated with a cardiac disease, most commonly some form of cardiomyopathy, according to research conducted by Vanderbilt researchers. Results would justify routinizing genetic testing of young afib patients, the researchers said.
New Gene Identified as a Driver in Hypertrophic Cardiomyopathy
A rare mutation of the ALPK3 gene has been shown to result in more serious cases of hypertrophic cardiomyopathy.
HCM Patients Experience Cardiovascular Comorbidities
A company developing a new therapy for hypertrophic cardiomyopathy released data recently showing that people with the obstructive form of the disease often develop hypertension, atrial fibrillation and other forms of cardiovascular disease.
Study Finds Racial Differences in HCM
Black HCM patients were more likely than White HCM patients to have mid-ventricular obstruction, according to recently reported findings.
Atrial Fibrillation May Make HCM Even More Dangerous
Japanese researchers say their study suggests that atrial fibrillation may trigger adverse events in HCM patients.
Mavacamten Has Potential to Adjust Life Years, But Isn't as Cost Effective as Expected
At a placeholder price of $75,000 per year for mavacamten used along with standard first-line treatment for symptomatic obstructive hypertrophic cardiomyopathy was above the threshold of $150,000 per QALY.
Mavacamten, First-in-Class Therapy, May Soon Be Available for Hypertrophic Cardiomyopathy
Positive trial results were reported in The Lancet last year. The FDA is scheduled (the PDUFA date) to make a decision on the application for approval early next year.
What's New in Hypertrophic Cardiomyopathy, With Gregory Weiss, MD
Hypertrophic cardiomyopathy or HCM is one of the most common genetic or congenital cardiac diseases. Affecting as many as 1 in 500 people, HCM is characterized by large increases in cardiac mass, in particular, left ventricular mass. Such enlargement predisposes seemingly healthy sufferers to sudden death at young ages.
2 Clarke Drive Cranbury, NJ 08512